BR1N-129.5 [PTA-4304] (ATCC® CRL-13022)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma: B lymphocyte; somatic cell hybri  / 

Permits and Restrictions

View Permits

Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma: B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Applications
These antibodies can be used to detect BRCA1 mutations.
Animals were immunized with purified bacterially-expressed fusion proteins containing BRCA1 amino acids 1 to 304. Spleen cells were fused with the mouse non-secretory myeloma cell line P3.653. Monoclonal antibodies BR1N.129.5 (ATCC PTA-4304) and BR1N-411.4 (ATCC PTA-4305) are against the N-terminal region of a BRCA1 polypeptide (amino acids 1 to 304).
Storage Conditions liquid nitrogen vapor phase
Derivation
Animals were immunized with purified bacterially-expressed fusion proteins containing BRCA1 amino acids 1 to 304. Spleen cells were fused with the mouse non-secretory myeloma cell line P3.653. Monoclonal antibodies BR1N.129.5 (ATCC PTA-4304) and BR1N-411.4 (ATCC PTA-4305) are against the N-terminal region of a BRCA1 polypeptide (amino acids 1 to 304). Monoclonal antibodies BR1H-788.6 (ATCC PTA-4301), BR1H-945.2 (ATCC PTA-4303) and BR1H-826.5 (ATCC PTA-4302) are against a portion of a BRCA1 polypeptide between the N-terminal and C-terminal regions of the BRCA1 polypeptide (amino acids 1360 to 1555). Monoclonal antibodies BR1S-218.1 (ATCC PTA-4307), BR1S-060.2 (ATCC PTA-4306), BR1S-384.5 (ATCC PTA-4308), and BR1S-425.1 (ATCC PTA-4309) are against the C-terminal region of a full-length BRCA1 polypeptide (amino acids 1840-1862). These antibodies can be used to detect BRCA1 mutations.
Comments
Animals were immunized with purified bacterially-expressed fusion proteins containing BRCA1 amino acids 1 to 304. Spleen cells were fused with the mouse non-secretory myeloma cell line P3.653. Monoclonal antibodies BR1N.129.5 (ATCC PTA-4304) and BR1N-411.4 (ATCC PTA-4305) are against the N-terminal region of a BRCA1 polypeptide (amino acids 1 to 304). Monoclonal antibodies BR1H-788.6 (ATCC PTA-4301), BR1H-945.2 (ATCC PTA-4303) and BR1H-826.5 (ATCC PTA-4302) are against a portion of a BRCA1 polypeptide between the N-terminal and C-terminal regions of the BRCA1 polypeptide (amino acids 1360 to 1555). Monoclonal antibodies BR1S-218.1 (ATCC PTA-4307), BR1S-060.2 (ATCC PTA-4306), BR1S-384.5 (ATCC PTA-4308), and BR1S-425.1 (ATCC PTA-4309) are against the C-terminal region of a full-length BRCA1 polypeptide (amino acids 1840-1862). These antibodies can be used to detect BRCA1 mutations.
Complete Growth Medium HH4 Medium supplemented with 10% fetal bovine serum
Cryopreservation
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37.0°C
Isotype mouse IgG1
Name of Depositor Hybritech, Inc.
References

Li H, et al. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277: 20965-20973, 2002. PubMed: 11916966

Knott CL, Kuus-Reichel K. Methods of detecting BRCA1 mutations. U.S. Patent 6,514,713 dated Feb 4 2003

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Li H, et al. A novel tricomplex of BRCA1, Nmi, and c-Myc inhibits c-Myc-induced human telomerase reverse transcriptase gene (hTERT) promoter activity in breast cancer. J. Biol. Chem. 277: 20965-20973, 2002. PubMed: 11916966

Knott CL, Kuus-Reichel K. Methods of detecting BRCA1 mutations. U.S. Patent 6,514,713 dated Feb 4 2003